日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Management of chronic rheumatic diseases in women 18-45 years of age in Asia Pacific: insights from patient and clinician surveys

亚太地区18-45岁女性慢性风湿病管理:来自患者和临床医生调查的见解

Tanaka, Yoshiya; Barrett, Claire; Hirano, Yuji; Ikeda, Kei; Paizis, Kathy; Sameshima, Azusa; Mountian, Irina; Wong, Priscilla C

Proposal for capturing patient experience through extended value frameworks of health technologies

通过扩展的健康技术价值框架来捕捉患者体验的提案

Inotai, András; Jakab, Ivett; Brixner, Diana; Campbell, Jonathan D; Hawkins, Neil; Kristensen, Lars Erik; Charokopou, Mata; Mountian, Irina; Szegvari, Boglarka; Kaló, Zoltán

Patient Satisfaction with CIMZIA(®) (Certolizumab Pegol) AutoClicks(®) in the UK

英国患者对 CIMZIA®(赛妥珠单抗)AutoClicks® 的满意度

Bailey, Kathryn; Mountian, Irina; Bruggraber, Richard; Sunderland, Kerri; Tilt, Nicola; Szegvari, Boglarka

Development and psychometric evaluation of the assessment of self-injection questionnaire: an adaptation of the self-injection assessment questionnaire

自我注射评估问卷的开发和心理测量学评价:自我注射评估问卷的改编版

Pompilus, Farrah; Ciesluk, Anna; Strzok, Sara; Ciaravino, Valerie; Harris, Kristina; Szegvari, Boglarka; Mountian, Irina; Cleanthous, Sophie; Meunier, Juliette

A Companion App to Support Rheumatology Patients Treated with Certolizumab Pegol: Results From a Usability Study

一款支持接受 Certolizumab Pegol 治疗的风湿病患者的配套应用程序:一项可用性研究的结果

Domańska, Barbara; Vansant, Stijn; Mountian, Irina

A portfolio of biologic self-injection devices in rheumatology: how patient involvement in device design can improve treatment experience

风湿病学领域生物制剂自注射装置组合:患者参与装置设计如何改善治疗体验

van den Bemt, Bart J F; Gettings, Lynda; Domańska, Barbara; Bruggraber, Richard; Mountian, Irina; Kristensen, Lars E

Using Patient Feedback to Optimize the Design of a Certolizumab Pegol Electromechanical Self-Injection Device: Insights from Human Factors Studies

利用患者反馈优化赛妥珠单抗聚乙二醇化电机械自注射装置的设计:来自人因工程研究的启示

Domańska, Barbara; Stumpp, Oliver; Poon, Steven; Oray, Serkan; Mountian, Irina; Pichon, Clovis

A Targeted Literature Review Examining Biologic Therapy Compliance and Persistence in Chronic Inflammatory Diseases to Identify the Associated Unmet Needs, Driving Factors, and Consequences

一项针对慢性炎症性疾病生物疗法依从性和持续性的文献综述,旨在确定相关的未满足需求、驱动因素和后果

Maniadakis, Nikos; Toth, Emese; Schiff, Michael; Wang, Xuan; Nassim, Maria; Szegvari, Boglarka; Mountian, Irina; Curtis, Jeffrey R

Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study

在既往未接受过DMARD治疗且预后不良的早期活动性类风湿关节炎患者中,塞妥珠单抗聚乙二醇联合剂量优化的甲氨蝶呤:一项随机、双盲、安慰剂对照的III期研究的1年结果

Emery, P; Bingham, C O 3rd; Burmester, G R; Bykerk, V P; Furst, D E; Mariette, X; van der Heijde, D; van Vollenhoven, R; Arendt, C; Mountian, I; Purcaru, O; Tatla, D; VanLunen, B; Weinblatt, M E

Long-Term Maintenance of Certolizumab Pegol Safety and Efficacy, in Combination with Methotrexate and as Monotherapy, in Rheumatoid Arthritis Patients

在类风湿性关节炎患者中,长期维持塞妥珠单抗聚乙二醇化物(Certolizumab Pegol)的安全性和有效性,包括联合甲氨蝶呤治疗和单药治疗

Fleischmann, Roy; van Vollenhoven, Ronald F; Vencovský, Jiri; Alten, Rieke; Davies, Owen; Mountian, Irina; de Longueville, Marc; Carter, David; Choy, Ernest